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The exceptions to patentable inventions are reviewed and analyzed. These are Sections 3, 4 and 5 of The Patents Act, 1970. 
They are accompanied with examples that demonstrate that it is not sufficient for the inventions to satisfy just the three criteria 
of patentability. The working of an invention should also promote and address public order, social harmony, rights of farmers 
and public health concerns. Patentable inventions that concern us most are related to agriculture and human health. The Patent 
Laws while supporting inventors must also provide for equitable distribution of the benefits of the invention across all sections 
of the society. In the broader scheme of things, the laws governing what inventions can be patented and what cannot be patented 
should be in harmony with the provisions of the TRIPS Agreement administered by WTO. 
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Inventions that cannot be patented form a very important 
component of every jurisdiction of a country.
1
 In India 
Section 3, 4, and 5 (omitted since 1.1.2005) of the 
Patents Act, 1970
2 
(hereinafter the Act) enumerate 
on non-patentable inventions.
3
 Section 3 is formally 
titled ― What are not inventions, Section 4 is formally 
titled ― Inventions relating to atomic energy not 
patentable. Section 5 is omitted as per the Patents 
(Amendment) Act 2005 to make way for product 
patents. There are two types of patents granted: patents 
for products and patents for process. Prior to the Patents 
(Amendment) Act 2005, India like most developing 
countries granted only process patents. It offered less 
protection to the inventor because the same product 
could be manufactured by different ways and there 
would be more than one manufacturer. The 
pharmaceutical industry benefitted hugely from this 
arrangement. The companies would manufacture the 
generic versions of the newly discovered drugs. On the 
other hand the generic versions were made available and 
affordable by the large masses in our society. Product 
patents offer higher level of protection to the inventor 
because it implies that no one can manufacture the 
product irrespective of the process used except with the 
consent of the inventor. Products will include medicines, 
drugs, agrochemicals, metal alloys, and products that are 
used in semiconductor devices or solid state devices in 
general and microorganisms. 
TRIPS (Trade Related Aspects for Intellectual 
Property Rights) Agreement administered by WTO 
follow the product patent regime. The 2005 Amendment 
to the Indian Patents Act 1970 omitted the Section 5 
which prohibited product patent thus setting the stage for 
fully aligning the Indian patent system with the 
provisions of TRIPS – an effective step in establishing 
India as global player in the world ecosystem of 
Intellectual Property. TRIPS provides for minimum 
standards in order for an invention to qualify for a grant 
of patent. The three criteria of patentability namely: 
novelty, inventive step which is non-obviousness to a 
person skilled in the art and industrial applicability are 
universally accepted.
4
 Novelty is searched by 
examination of prior art which includes patent and non-
patent literature. Non-obviousness is a difficult criterion 
and is best decided by the technical experts in the field 
and lastly, the industrial applicability test is passed if the 
invention is used and can be made by the industry.
5 
The 
phrase ― technological advance‖ is often encountered in 
defining these criteria and describing an invention. In the 
field of intellectual property an invention is mostly 
synonymous with technology. Simply put it means 
that the invention is a technological model or a process 
and is technologically superior to the existing 
apparatus/machine/article or process. 
Section 3 of the Patents Act, 1970 
Section 3(a) forbids inventions which are frivolous. 
Frivolous inventions for the purpose of this Act are 
—————— 
†Email: sonalikokane@gmail.com 




classified as those which go against the laws of 
nature. Many inventions based on perpetual  
motion giving rise to perpetual machines are filed. 
The laws of thermodynamics are violated here. A 
machine with 100% efficiency can never be 
accomplished. In practice, we know that 55% 
efficiency is attainable with ingenuity and clever 
design of the machine. Another example could be a 
clock with ten hours calibration. 
Section 3(b) says that inventions whose 
commercial exploitation is harmful to public order 
and morality cannot be patented. Let‗s say someone 
comes with an invention where a recombinant gene is 
introduced in the flower whereby butterflies are not 
attracted to it. Human genomes are modified and such 
modification is harmful under the law. Human 
cloning is also unlawful under this section. Inventions 
relating to bio-war, bio-terrorism, gambling machines, 
counterfeiting of currency cannot be patented. 
Objections to stem cell research also fall under this 
category since this research makes use of human 
embryos. Research has led to obtaining stem cells 
from non-embryonic sources such as cord blood and 
amniotic cell lining. Embryos obtained from wasted 
in-vitro fertilization cycles, aborted foetuses and 
asexually grown embryos are deemed to be within 
ethical considerations. European countries, Canada 
and the United States provide stringent conditions for 
research due to the ethical issues involved. Belgium, 
Israel, South Korea, China, UK and India actively 
support research in this field. Policy makers use 
Section 3(b) as a primary reason behind discouraging 
research in Stem cell therapy. The first human 
embryonic stem cell patents were U.S. Patent Nos. 
5,843,780, 6,200,806, and 7,029,913 issued to James 
Thomson, University of Wisconsin. Inventions based 
on stem cell research satisfy all the three criteria of 
patentability and is very much a patentable subject 
matter in the Indian jurisdiction. 
Section 3(c) concerns with living or non-living 
things that occur in nature and forbids their patenting. 
Discovering a living or non-living thing is a discovery 
and not an invention. An example could be discovery 
of a galaxy or an asteroid or a species of plant or 
animal. It also concerns with formalism of an abstract 
theory or discovery of a scientific phenomenon/ 
fact/principle. These are not inventions and hence  
not subject to patentability. The discovery of the 
phenomenon of electromagnetic induction by Michael 
Faraday was unpatentable. Based on the same 
principle, Graham Bell came up with the invention of 
telephone and even acquired a patent for it (US 
Patent: 174,465, granted in 1876) 
Section 3(d) famously called as the Grandfather’s 
Clause is the most controversial clause, having given 
rise to the popular case of Novartis v Union of India.
6 
The litigation went on for seven years. This is also the 
clause that juxtaposes health issues against 
Intellectual property of the crucial life-saving drugs 
protected by patents. Section 3(d) really is made up of 
three parts. The first part of this clause deals with 
therapeutic efficacy. It says that a mere discovery of a 
new form of a known substance (for which a patent 
may already be in existence) which does not result in 
the enhancement of the known efficacy of that 
substance then that substance is not eligible to get a 
patent. For the sake of the clause the new form of a 
known substance is described as its salt, ester, 
polymorph, isomer, derivative or a metabolite. In 
2003, the patent application of Novartis claimed the 
final form of Gleevac which is the beta crystalline 
form of the known substance Imitanib mesylate, an 
anti-cancer drug. Novartis claimed that Gleevac 
showed better stability, better storage properties and 
30% increase in bioavailability. The Supreme Court 
of India ruled that this is not enough, that this does 
not prove that the beta crystalline form has better 
therapeutic efficacy over imitanib mesylate. Novartis 
lost the case.
7 
The purpose of 3(d) is also to prevent 
what we call as patent evergreening.
8
 But then again 
Pharmaceutical companies spent millions of dollars 
and about a decade of research to invent a drug. It is 
justifiable that they will look towards regaining the 
spent amount through market share. Also can we 
quantify efficacy? There are numerous research 
papers claiming to do so. But close examination 
reveals that the efficacy is always indirectly 
expressed. There we are at the cross roads.  
What matters most? Public health or IP of the 
pharmaceutical companies who have spent millions  
of dollars and plenty of years to come up with a new 
drug.
9 
The second part of this clause is that a 
secondary use of a known substance cannot be 
patented. The third part is that if one is using a known 
process than that known process should lead to a new 
product or if one is using a known process involving 
reactants then the known process should use at least 
one new substance or reactant. 
Section 3(e) states a substance obtained by a mere 
admixture resulting only in the aggregation of the 




properties of components thereof or the process 
producing such a substance cannot be patented. 
Prominent examples in this category are the food 
recipes and herbal mixtures. The food recipes are 
patentable only if there is human intervention in form 
of baking, roasting, steaming and so on. The 
patentability of food recipes should be really  
decided on case-to-case basis. Herbal mixtures attract 
a lot of patents. Here again the applicant must 
demonstrate that the components in the mixture are 
not just acting independently of each other but are 
acting synergistically to give the desired effect. 
Demonstration of synergy supported by biological 
data will help to overcome the objections raised by 
the patent office based on this clause. Another factor 
that concerns herbal mixtures is traditional 
knowledge. If the herbal mixtures uses herbs then the 
objections to patentability could be raised based on 
Section 3(p). Nevertheless, the synergistic effect must 
be suitably demonstrated to overcome the objection 
that the components in any mixture are not just acting 
independently but synergistically. 
Section 3(f) states that mere rearrangement of 
devices functioning independently of each other in a 
known way is not an invention. The clause says that 
one cannot put two different things which work 
independently of each other and call it an invention. 
An example of putting a clock and a fan in a single 
cabinet or coupling a torch with a bucket are not 
patentable. Another example could be a smart phone. 
Section 3(g) is omitted by the Patents Amendment 
Act, 2002. Prior to the amendment it said that any 
method of testing used to improve the existing 
machine, article, apparatus or any other equipment 
cannot be patented. 
Section 3(h) states a method of agriculture or 
horticulture is not patentable. Straightforward 
examples could be methods of cultivating algae, 
mushrooms. Methods of improving soil quality and 
method involving green house effects are also not 
patentable under this clause. A rule of thumb to 
follow is any modifications of conditions related to 
growing plants where natural phenomena would 
pursue their inevitable course is non-patentable. 
Identification of inventive step becomes difficult in 
inventions involving natural phenomena such as 
growth of plants and germination of seeds. The 
difficulty here is to identify the inventive step - where 
the human intervention stops and natural processes 
take over. 
Section 3(i) states any method of treatment to 
render plants and animals free of diseases in order to 
increase their economic value or that of their products 
is not patentable. The method of treatment can be 
classified as medicinal (process of orally or through 
injections), surgical (stitch-free incision for removal 
of cataract or laser-based surgery), curative (plague 
removal from teeth, cleaning of Uterus), prophylactic 
(a method of vaccination), and Diagnostic methods. 
Diagnostic methods employ laws of nature in the 
sense that general physical parameters are considered 
and this fact makes diagnostic methods non- 
patentable inventions. However if someone invents a 
surgical knife, that would be a patentable subject 
matter. A general term for these methods is therapy. 
―therapy‖ includes prevention, cure and treatment  
of diseases. Under this clause, an applicant has to 
prove that the subject of his invention is not a 
therapy- is not a method of treatment. Stem cell 
therapy is an exception. 
Section 3(j) states what one cannot consider an 
invention under this act is any process for production 
and propagation of plants and animals, in whole or in 
part and seeds. Microorganisms are patentable subject 
matter if human intervention is responsible for their 
invention. As such microorganisms discovered 
directly from nature cannot be patented. Seeds which 
are the very symbol of life‗s renewal are primarily the 
subject of Section 3(j). The question is whether 
genetically modified seeds are patentable or not. The 
answer is yes: genetically modified seeds are 
patentable subject matter.
10
 Monsanto; a US biotech 
company developed bollworm resistant Bt cotton 
seeds by introducing a nucleic acid sequence. 
Monsanto‗s genetically modified seeds have 
transformed the company and are radically altering 
global agriculture.
11
 So far, the company has 
produced GM seeds for soybeans, corn, canola, and 
cotton. Many more products have been developed or 
are in the pipeline, including seeds for sugar beets and 
alfalfa. They applied for a patent for the cotton  
Bt seeds in India. The Indian Patent Office granted 
Patent No. 214436 (Date of Grant: 12 February 2008) 
to Monsanto Technology LLC for genetically 
modified cotton seeds. Monsanto filed a case against 
The Nuziveedu Seeds Ltd, a Hyderabad based 
company for infringement of their patent in 2016. 
Nuziveedu Ltd responded with a counterclaim for 
invalidity of the patent by virtue of Section 3(j). 
Indeed the Division Bench of Delhi High Court in 




2018 ruled in favour of Nuziveedu Ltd in the appeal 
against the Single Bench‗s order. But the Supreme 
Court of India restored the Single Judge‗s March 
2017 order and remanded the suit to the learned 
Single Judge for disposal in accordance with law in 
view of the importance of the question involved. In 
the strictest sense, it was not a method of propagation 
of production of plant because the genetic 
modification introduced by the scientists at Monsanto, 
consisted of introducing a nucleic sequence which 
cannot propagate on its own. Can we call this a 
loophole or not? India enacted 'The Protection of 
Plant Varieties and Farmers' Rights' (PPVFR) Act, 
2001 to protect the farmers from unfair competition. 
However, the argument continues whether a single 
company should be encouraged by IPR laws to decide 
what we should put on our table. On the other hand 
the Monsanto cotton seeds propelled India into  
one of the top producers of the fibre. The Monsanto 
verdict included India among nations that respect 
biotechnological inventions. Another subject matter 
of Section 3(j) is whether genetically modified plants 
and animals are patentable subject matter or not. Here 
are the exact words of Section 3(j):―Plants and 
animals in whole or any part thereof other than 
microorganisms but including seeds, varieties and 
species and essentially biological processes for 
production or propagation of plants and animals. 
The essentially biological processes can be interpreted 
as including naturally occurring plants and animals 
and not including microbiologically processes which 
encompass genetic modifications. These inventions 
fall in the field of biotechnology. A casual search on 
in PASS (Indian Patents Database, http://www.ipindia. 
nic.in/writereaddata/Portal/IPOGuidelinesManuals/1_
38_1_4- biotech-guidelines.pdf) will lead to some 
examples of biotechnology inventions. Prior to the 
2002 Amendment of the Patents Act, 1970, inventions 
relating to living organisms were non-patentable 
subject matter. Patents were granted only for 
inventions based on non-living subject matter such as 
vaccines, antibodies and proteins. After the 2002 
Amendment, inventions relating to living organisms, 
both natural and artificial, became patentable subject 
matter. The living substances also include nucleic 
acid and any other material that have replicating 
properties. Any process leading to manufacture of a 
living organism or living matter is an invention and 
eligible for patent protection. In the landmark 
Dimminaco Case, the process for which protection 
was claimed resulted in a living organism which was 
a live vaccine for treating the poultry infection of 
Bursitis. The case opened the doors for biotechnology 
patents where process and products were related to 
living matter. 
Section 3(k) states that mathematical models, 
business methods, computer program per se and 
algorithms are non-patentable subject matter. 
Mathematical models are considered to be acts of 
mental skill. A method of calculation, formation of 
equations, finding square roots, and cube roots are 
examples of mathematical model. The term business 
method involves a whole gamut of activities in a 
commercial enterprise relating to transaction of goods 
or service. With development of technology, business 
activities have grown tremendously through e-
commerce and related to B2B (Business-to-Business) 
and B2C (Business-to-Consumer) transactions. An 
algorithm is defined as  ―procedure for solving a given 
type of mathematical problem‖. A mathematical 
problem is based on law of nature and therefore is 
excluded from patentability. Computer programs are 
protected by Copyright and not by patents.
12,13
 A rule 
of thumb is to consider a computer program as 
patentable subject matter only if it is written for a 
specific hardware. A computer program written to 
control temperature for instance, cannot be patented 
because it can be used on practically any hardware 
which needs temperature control. Computer programs, 
whatever their form or mode of expression is protected 
by the WIPO Copyright Treaty (WCT, 1996). 
Section 3(l) basically involves creations that lend 
themselves to copyright protection. These are literary 
creations, drama, paintings, creation of art, song lyrics, 
music, translations, adaptations, cinematographic works, 
multimedia production and the broadcasters‗right. They 
fall under the copyright act of India, 1957. 
Section 3(m) states ―a mere scheme or rule or 
method of performing mental act or method of 
playing game is not an invention because these are 
considered to be an outcome of mere mental process. 
A method of playing chess, a method of teaching, 
method of learning are not patentable because they do 
not result in any product or an invention. 
Section 3(n) states ―Presentation of Information‖ is 
not an invention. Information that is presented by 
visual, audible or tangible modes employing words, 
codes, signal, symbol, diagrams is not patentable. The 
basis of this clause is that presentation of information 
does not involve any technological expertise or 




advance. Since Patent System is meant primarily for 
technological inventions, any mode of presenting 
information such as a railway timetable comes outside 
of patentable matter. 
Section(o) states topography of integrated circuits 
cannot be patented. The 3-D configuration of Layout 
designs of Integrated circuits is protected by the 
Semiconductor Integrated Circuits Layout Designs 
Act, 2000. This law was passed to confirm with the 
TRIPS agreement to which India is a signatory and 
which is administered by WTO. This Act empowers a 
registered proprietor and protects his IP from 
infringement. 
Section (p) states that any invention that makes use 
of components that are traditional knowledge and 
claims the aggregation/duplication of properties 
arising out of these is not patentable under this clause. 
Traditional knowledge comprises of knowledge that 
has been in existence for many years, sometimes 
centuries old, belonging to a certain country or 
community. To put it simply, traditional knowledge is 
prior art. Herbal mixtures employing ayurvedic 
substances are common examples. The well known 
examples are 1) the revocation of the Neem Patent by 
European Patent Office in 2004 granted to US 
Department of Agriculture and a multinational WR 
Grace and 2) revocation of the Haldi Patent in 1995 
by USPTO granted to two researchers, Soman K. Das 
and Harihar Kohli of the University of Mississippi 
Medical Center. Their patent claims covered the oral 
and topical use of turmeric powder to heal surgical 
wounds and ulcers. There have been many patents 
granted to inventions involving traditional knowledge. 
A patent was granted for a process for producing 
herbal water containing tulsi extracts. As far as 
patentability issues are concerned, the applicant  
must take permission from National Biodiversity 
Authorities if he is using a genetic resource.
14
 
Section 4 and Section 5 of the Patents Act, 1970 
Section 4 of the Patents Act, 1970 excludes patents 
based on use of Atomic energy falling within subsection 
(1) of Section 20 of Atomic Energy Act 1962. The 
inventions may be significant to defense purposes of 
India. Not all inventions based on atomic energy are 
non-patentable or significant to the defense purpose of 
India but the decision lies with the Central Government 
and the Patent Office acts accordingly. Section 5 was 
omitted by the Patents Amendment Act, 2005. Prior to 
the amendment the section prohibited patents on 
products pertaining to food industry, medicine and 
agrochemicals, alloys and inter-metallic compounds 
used in semi-conductor industry. The omission of this 
section effectively lead the way to obtaining product 
patents in India. The industry most affected by this 
omission was the pharmaceutical companies which were 
involved in manufacture of generic drugs. Before the 
amendment these companies made the generic versions 
of these product-medicines by finding alternate process 
to the patented process. The World Trade Organization 
administers the treaty of TRIPS. India is a signatory to 
this treaty (1 January 1995).
15
 In order to make the IP 
laws of India TRIPS-compliant, India brought in the 
Amendments from time to time. 
 
Analysis 
The inventions can generally be classified as 
absolute exceptions, conditional exceptions and  
non-inventions (Table 1). Kindly note these are just 
the views of the author as being another aspect of 
these non-patentable inventions. The classification 
generally helps to remember the exceptions in their 
order. In the table below the overlapping exceptions 
are given in Italics. 
Absolute exceptions are the ones where there is 
absolutely no scope for patentability. These arise from 
two reasons: 1) frivolity 2) policy and legal reasons. 
Table 1 — Classification of inventions 
Absolute exceptions Conditional exceptions Non-inventions 
3(a): Frivolity 3(d): Known process 3(c): Natural things, theory 
3(b):Public order 3(d): Grandfather‗s clause 3(d): New use 
3(h): Agriculture 3(e): Admixture & synergy 3(f): Known devices 
3(i): Treatment 3(k): Computer programs 3(l): Copyright 
3(j): Biological process 3(p): Traditional Knowledge 3(m): Scheme/rule/method 
3(o): Integrated circuits  3(n): Presentation 
  3(j): Biological process 
  3(k): Computer programsetc. 
  3(p):Traditional knowledge 
 




Inventions based on 3(a) are frivolous inventions as 
they flout the laws of nature. In these cases, the Patent 
Office will usually ask for a model to be submitted. 
3(b) inventions are harmful to public order and 
morality. Inventions under this clause may satisfy all 
the conditions of novelty, non-obviousness and 
industrial application. Despite this, they cannot be 
patented as they are harmful to society. It‗s a matter 
of policy as their use will lead to lawlessness in 
society. Inventions of Sections 3(h), 3(i), 3(j) may 
satisfy the aforementioned conditions but yet are not 
conducive to growth and progress of society. 3(h) and 
3(j) protects the farmer‗s rights.
16
 3(i) protects the 
right of every citizen to access for medical treatment. 
As mentioned earlier the intellectual property 
associated with integrated circuits is protected by the 
SICLD Act. Government will make these policies and 
accordingly enact laws to support them. Any 
invention that goes against the existing legal and 
policy issues will be ineligible for patentability. 
Conditional exceptions are the ones which are non- 
patentable but with suitable modifications can become 
patentable. 3(d) covers the grandfather‗s clause which 
says that if the inventor can demonstrate greater 
therapeutic efficacy then the existing one, the 
invention can be patented. Also under the same 
clause, it is clearly mentioned that if the known 
process employs at least one new reactant, that known 
process can be patented. 3(e) is about synergy without 
which the invention is non-patentable. An admixture 
is patentable subject to the condition that the applicant 
proves the synergy associated with the components. A 
computer program falls in the domain of copyright 
but if specific hardware is designed to go with 
specific software, then that computer program 
becomes eligible for patentability. The reason why 
computer programs are not patentable is because most 
of them are incremental in nature and identification of 
inventive step becomes nearly impossible. Traditional 
knowledge is actually prior art which a given 
community may have been practicing for centuries. 
But if the invention involves considerable human 
intervention, then that invention although based on 
Traditional knowledge becomes patentable. However, 
the applicant for patent must disclose the source of the 
traditional knowledge and materials and also if 
required take the permission from the relevant 
authority.
17
 It is also desirable that should the working 
of patented invention lead to profits, the community 
to whom the traditional knowledge belongs, have a 
right to a share in the profits.
18
 
The easiest category to understand is the category 
which covers the non-inventions. 3(c) clause leads to 
non-inventions. To formulate a scientific theory or 
discover a law of nature requires extreme human 
intellect and intervention. Yet it is not an invention. 
Also anything existing in nature encompassing all 
living and non-living things are a discovery and not 
an invention. The part of the 3(d) clause where a mere 
secondary use of a known substance is discovered 
does not qualify as an invention and 3(f) pertains to a 
mere rearrangement of known devices which function 
in a known way. 3(l) pertains to copyrighted material 
which concerns with creative forms of art and not 
inventions. 3(m) is a mental process not leading to 
any invention. Activity under clause 3(n) is not an 
invention. It does and can attract copyright protection 
under copyright laws though it cannot lead to an 
invention. Biological process in 3(j) is an event that 
occurs in nature. If a strand of DNA is introduced in 
the genetic code of living thing and if this strand 
replicates itself, it is not an invention because the 
DNA strand anyway is doing its job: that of 
replicating itself. By that virtue alone inventions 
claiming these become non-patentable. Computer 
programs as such are considered literary creations and 
Table 2 — Relevant sections under different categories 
Subject Patentable/Non-patentable Relevant Section 
Microorganisms Patentable after the patent of Ananda Mohan 
Chakrabarty 
Omission of Section 5 
Drugs/medicines/agrochemicals/metallic 
compounds/microorganisms 
Patentable after the amendment of 2005 Omission of Section 5 
Stem cell therapy Patentable Section 3(b) 
Genetically modified plants and animals May be Patentable. Section 3(j) gives no clear provision 
Biotechnology inventions Patentable Section 3(j) 
Genetically modified seeds Patentable after the Monsanto case Section 3(j) 
Human cloning Non-patentable Section 3(b) 
Computer software Non-patentable (most of the times) Section 3(l) 
Algorithms Non-patentable (most of the times) Section 3(k) 




fall in the domain of copyright. Algorithms arise from 
scientific principle or from some law of nature. An 
algorithm is another expression of a scientific law and 
therefore not an invention. However consider the US 
Patent No. 4,405,829 granted to Adelman et al in 
1983 for the famous RSA algorithm for public-key 
cryptography. Business methods here in this context 
mean ideas governing commercial activities. 
Examples could be online marketing, advertising and 
online trading of shares. A business method is non- 
patentable in India. But then again consider the US 
Patent No. 6,041,345 granted to Steven Levi et al of 
Microsoft Corporation for Advanced Systems Format 
– a format for storing and streaming media. Ideas 
cannot be patented just as they cannot be the subject 
matter of copyright even. But the expression of idea 
leading to a literary creation can be copyrighted and 
an expression of the idea leading to an invention can 
be patented. Traditional knowledge without any 




India is a party to the TRIPS Agreement. The 2005 
Amendment of The Patents Act, 1970, by omission of 
Section 5 as well as through various amendments 
made the intellectual property laws of India fully 
TRIPS-complaint. Several questions are always 
raised: Are microorganisms patentable?
19,20
 Yes, a 
microorganism whose discovery involves human 
intervention is patentable and qualifies for a product 
patent. Is human cloning patentable? No, because 
human cloning is not subject to patentability on the 
grounds of Section 3(b).Is stem cell research 
patentable?
21,22
 Are genetically modified seeds 
patentable? Yes, they are. Are genetically modified 
plants and animals patentable? This article provides 
some insight into these answers. Any invention must 
satisfy the three universal criteria of patentability 
namely, novelty, inventive step (non-obviousness) 
and industrial applicability. Inventions that concern 
biological processes and software are challenging 
because in these cases the identification of inventive 
step becomes difficult. In the former it is important to 
identify the step where human intervention stops and 
biological process takes over. In the latter the 
incremental changes make the identification of 
inventive step a very difficult process. These 
conclusions can be summarized in a form of table  
to have answers at a single glance (Table 2). 
The provisions of the law give us broad answers 
but more often than not it becomes necessary to 
investigate the inventions on case-by-case basis. 
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